{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["26(34)"],"submitter":["Fernandez-Ramos D"],"pubmed_abstract":["<h4>Background</h4>Arachidyl amido cholanoic acid (Aramchol) is a potent downregulator of hepatic stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of steatohepatitis. In a phase IIb clinical trial in patients with nonalcoholic steatohepatitis (NASH), 52 wk of treatment with Aramchol reduced blood levels of glycated hemoglobin A1c, an indicator of glycemic control.<h4>Aim</h4>To assess lipid and glucose metabolism in mouse hepatocytes and in a NASH mouse model [induced with a 0.1% methionine and choline deficient diet (0.1MCD)] after treatment with Aramchol.<h4>Methods</h4>Isolated primary mouse hepatocytes were incubated with 20 μmol/L Aramchol or vehicle for 48 h. Subsequently, analyses were performed including Western blot"],"journal":["World journal of gastroenterology"],"pagination":["5101-5117"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7495035"],"repository":["biostudies-literature"],"pubmed_title":["Arachidyl amido cholanoic acid improves liver glucose and lipid homeostasis in nonalcoholic steatohepatitis <i>via</i> AMPK and mTOR regulation."],"pmcid":["PMC7495035"],"pubmed_authors":["Lu SC","van Liempd SM","Goni FM","Azkargorta M","Sot J","Delacruz-Villar L","Bilbao J","Serrano-Macia M","Mato JM","Pagano M","Bizkarguenaga M","Alonso C","Lopitz-Otsoa F","Martinez-Chantar ML","Mosca L","Hayardeny L","Iruarrizaga-Lejarreta M","Tsvirkun D","Fernandez-Ramos D","Elortza F"],"additional_accession":[]},"is_claimable":false,"name":"Arachidyl amido cholanoic acid improves liver glucose and lipid homeostasis in nonalcoholic steatohepatitis <i>via</i> AMPK and mTOR regulation.","description":"<h4>Background</h4>Arachidyl amido cholanoic acid (Aramchol) is a potent downregulator of hepatic stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of steatohepatitis. In a phase IIb clinical trial in patients with nonalcoholic steatohepatitis (NASH), 52 wk of treatment with Aramchol reduced blood levels of glycated hemoglobin A1c, an indicator of glycemic control.<h4>Aim</h4>To assess lipid and glucose metabolism in mouse hepatocytes and in a NASH mouse model [induced with a 0.1% methionine and choline deficient diet (0.1MCD)] after treatment with Aramchol.<h4>Methods</h4>Isolated primary mouse hepatocytes were incubated with 20 μmol/L Aramchol or vehicle for 48 h. Subsequently, analyses were performed including Western blot","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Sep","modification":"2025-05-29T19:38:24.39Z","creation":"2020-10-01T07:08:36Z"},"accession":"S-EPMC7495035","cross_references":{"pubmed":["32982112"],"doi":["10.3748/wjg.v26.i34.5101"]}}